The China National Medical Products Administration has approved the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) for use in patients with unresectable hepatocellular carcinoma (HCC) who have not received previous systemic therapy.1 The regulatory decision was based on data from the ...
(uHCC) more in the first-line setting remains controversial.Objective In this analysis, we compared the clinical outcomes of lenvatinib monotherapy with atezolizumab plus bevacizumab combination therapy in advanced uHCC in real-world clinical... BC Wang,BH Kuang,GH Lin - 《Targeted Oncology》 被引...
2 week off cycle (n = 101), atezolizumab monotherapy at 1200 mg IV every 3 weeks (n = 103), or to atezolizumab at 1200 mg IV plus bevacizumab at 15 mg/kg IV (n = 101) both given every 3 weeks. Treatment...
Atezolizumab Plus Bevacizumab as First-Line Treatment for Patients With Metastatic Nonsquamous NSCLC With High Tumor Mutation Burden JAMA Oncology Save Recommend Share Sign in to PracticeUpdate Only registered members have full access to Pra...
paclitaxel (ABCP) versus the standard-of-care bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy-naive patients with non-squamous non-small-cell lung cancer. Here, we report the efficacy of ABCP or atezolizumab plus carboplatin plus paclitaxel (ACP) versus BCP in key patient ...
更新 大幅提高文件上传限制,最高150M (2024-4-1) 科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。实时播报 JamesPei上传了应助文件 1秒前 holiday发布了新的文献求助20 1秒前 小二郎的应助被CQ采纳,获得10 1秒...
对于在治疗目的切除或消融术后仍有肝细胞癌复发高风险的患者,尚未建立辅助治疗。该研究的目的是评估atezolizumab联合bevacizumab主动监测在高危肝癌患者中的疗效。近日,南京中医药大学金陵医院秦叔逵等团队合作在国际知名医学期刊Lancet (IF=169)在线发表题为“Atezolizumab plus bevacizumab versus active surveillance in ...
“Based on this announcement, adjuvant atezolizumab plus bevacizumab is likely to become a new standard of care for patients with resectable HCC. There are still several unanswered questions. Patients on this study were heterogeneous, and subset analysis may provide information about whet...
A comprehensive review of clinical data of atezolizumab plus bevacizumab for the treatment of unresectable HCC. EP: 1.The Evolving Landscape of Hepatocellular Carcinoma Now Viewing EP: 2.Atezolizumab plus Bevacizumab in the Treatment of Unresectable HCC EP: 3.AASLD 2023 Updates: HIMALAYA Trial for ...
(Atezo) plus bevacizumab (Bev) is the preferred first-line treatment of HCC patients with BCLC stage C.20–22 The IMbrave150 trial established the position of Atezo-Bev as the first-line treatment for advanced HCC.20 However, the patients with large uHCC were underrepresented in the IMbrave...